AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04197518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neuro trax system and a neurology test.
Description: the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving.
Study NCT00805610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatocyte Transplantation
Description: Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
Study NCT03674333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
Study NCT03674333 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - a sugar pill
Study NCT00855387 — intervention group
Intervention type: OTHER
Intervention: No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel
Description: No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
Study NCT03870685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Transversus Plane block
Study NCT03870685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Site Infiltration
Description: Surgical Site Infiltration
Study NCT03870685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: liposomal bupivacaine
Study NCT04932044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Sleep Facilitation Program
Description: It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
Study NCT04932044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Receives routine care and provide general discharge care and nursing guidance.
Study NCT03943147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT03943147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT03943147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days
Study NCT04527055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis Bb12
Description: The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan).
Study NCT03832309 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speaking to them as a regualar person
Description: During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
Study NCT03832309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speaking to them as a regualar person
Description: During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
Study NCT01660191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastin 4mg
Study NCT01660191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Study NCT01660191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg
Study NCT00818129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7295
Description: ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
Study NCT00818129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple ascending dose (tbd based on single dose results), oral solution
Study NCT04310956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y-Knot all-suture anchor
Description: Y-knot all-suture anchor will be implanted to participants
Study NCT04310956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biocomposite suture anchor
Description: Biocomposite suture anchor will be implanted to participants
Study NCT02214368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early application of NIV
Description: Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization.
Study NCT02214368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy
Description: Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
Study NCT02214368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention.
Study NCT02214368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional application of NIV
Description: Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
Study NCT01684163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13 5 mg/kg
Description: Intravenous administration of 5 mg/kg into arm.
Study NCT01684163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13 10 mg/kg
Description: Intravenous administration of 10 mg/kg into arm.
Study NCT03943147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days
Study NCT04932044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Receives routine care and provide general discharge care and nursing guidance.
Study NCT01826526 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TauroSept®
Description: 5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months.
Study NCT01826526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TauroSept®
Description: 5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months.
Study NCT02920606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Study NCT02920606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment
Study NCT00753688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZOPANIB
Description: 800 mg once daily orally
Study NCT00753688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo 800 mg once daily orally
Study NCT01929265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28
Study NCT01684163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of normal saline into arm.
Study NCT03003273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stoppage of antibiotics
Description: antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
Study NCT03003273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: amoxycillin/clavulanic acid
Description: In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
Study NCT03003273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
Study NCT02961166 — intervention group
Intervention type: DRUG
Intervention: IgM enriched Immunoglobulins
Description: Treatment for 3 days
Study NCT04412148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
Study NCT04412148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intralesional injection of saline
Study NCT03254602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment
Study NCT02619877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
Study NCT02619877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy conducted for patients with diabetic foot ulcer
Study NCT04527055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT04527055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT04527055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT02825446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty tibial arteries
Description: Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time.
Study NCT02825446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon
Description: Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time.
Study NCT01673659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Study NCT01673659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray
Study NCT01673659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study NCT01370304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and active Venlafaxine
Description: rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
Study NCT01370304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and sham Venlafaxine
Description: rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
Study NCT01370304 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS and active Venlafaxine
Description: rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
Study NCT02745496 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TRUS Biopsy
Description: Standard of Care Treatment
Study NCT02745496 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TRUS/FUSION Biopsy
Description: Interventional Treatment
Study NCT00521677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sage oral care
Description: Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
Study NCT00521677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional oral care
Description: Cleaning of oral cavity with menthol solution, TID
Study NCT01890096 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR 2 Fraction
Description: High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
Study NCT01890096 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR 1 Fraction
Description: High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
Study NCT05060692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bloot testing
Description: NFL measruments in serum
Study NCT01952743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation with Renal Denervation
Description: Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
Study NCT01952743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation alone
Description: Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
Study NCT03856359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 milligrams (MG)
Description: Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
Study NCT04149483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
Study NCT04149483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
Study NCT00310375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine: USAN Retigabine (International Nonproprietary Name)
Description: Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
Study NCT02982655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized BP lowering
Study NCT02982655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized BP lowering
Study NCT01718522 — intervention group
Intervention type: DEVICE
Intervention: sensor augmented pump (SAP)
Study NCT00573391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade, Thalidomide, and Dexamethasone
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles
Study NCT00573391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade, Melphalan, and Dexamethasone
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles
Study NCT00871663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
Study NCT00774124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
Study NCT00774124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 50 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 100 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)